- Home
- LANC vs CANF Comparison
LANC vs CANF Comparison
Compare LANC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANC
- CANF
- Stock Information
- Founded
- LANC 1961
- CANF 1994
- Country
- LANC United States
- CANF Israel
- Employees
- LANC N/A
- CANF N/A
- Industry
- LANC Packaged Foods
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- LANC Consumer Staples
- CANF Health Care
- Exchange
- LANC Nasdaq
- CANF Nasdaq
- Market Cap
- LANC N/A
- CANF 7.9M
- IPO Year
- LANC N/A
- CANF N/A
- Fundamental
- Price
- LANC $189.03
- CANF $1.20
- Analyst Decision
- LANC Buy
- CANF Strong Buy
- Analyst Count
- LANC 4
- CANF 2
- Target Price
- LANC $211.33
- CANF $14.00
- AVG Volume (30 Days)
- LANC 199.9K
- CANF 413.8K
- Earning Date
- LANC 04-30-2025
- CANF 04-29-2025
- Dividend Yield
- LANC 2.01%
- CANF N/A
- EPS Growth
- LANC 21.25
- CANF N/A
- EPS
- LANC 5.69
- CANF N/A
- Revenue
- LANC $1,900,130,000.00
- CANF $674,000.00
- Revenue This Year
- LANC $5.03
- CANF $461.72
- Revenue Next Year
- LANC $3.31
- CANF N/A
- P/E Ratio
- LANC $33.22
- CANF N/A
- Revenue Growth
- LANC 1.77
- CANF N/A
- 52 Week Low
- LANC $163.20
- CANF $1.22
- 52 Week High
- LANC $202.63
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- LANC 61.74
- CANF 37.12
- Support Level
- LANC $171.48
- CANF $1.22
- Resistance Level
- LANC $187.81
- CANF $1.82
- Average True Range (ATR)
- LANC 5.92
- CANF 0.13
- MACD
- LANC 1.55
- CANF -0.02
- Stochastic Oscillator
- LANC 96.70
- CANF 3.13
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).